Financings in Brief: Avitar
This article was originally published in The Gray Sheet
Avitar: Registration statement filed with the Securities and Exchange Commission for the offering of 13 mil. shares (including 12.7 mil. by the company and 361,000 by selling shareholders) has been declared effective, the firm states. The shares offered by the company would be issued if "redeemable warrants and certain other warrants were exercised." If all warrants were exercised, the aggregate exercise price would be about $21.6 mil. the firm states. "Proceeds, if any, will be used to continue to expand the business" and for "general working capital purposes," Avitar says...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.